Feature | Angiography | April 15, 2016

New Drug Ineffective in Preventing Contrast-Induced Kidney Injury

Placebo-controlled trial found no improvement in rate of acute nephropathy

Toshiba

Kidney ultrasound perfusion exam, courtesy of Toshiba.

April 15, 2016 — Patients treated with CMX-2043 — an investigational drug that has previously shown some ability to protect heart muscle from damage during stenting — saw no improved protection in their kidneys compared to placebo, according to research presented at the American College of Cardiology (ACC) 2016 meeting. 

Contrast media used in angiograms can cause damage to kidney cells, lower urine output and significantly reduce or even stop kidney function, especially in patients with diabetes or chronic kidney disease. According to the National Kidney Foundation, patients with both of these conditions have a 20 to 50 percent risk of kidney injury, also called nephropathy, when given contrast.

Currently, hydrating a patient before the imaging procedure is the best way to prevent contrast-induced kidney injury, but that process takes time and can be impractical in emergency situations.

“Contrast-induced acute kidney injury remains a really significant problem in the population,” said Deepak L. Bhatt, M.D., MPH, FACC, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital, professor of medicine at Harvard Medical School and lead author of the study. “It remains an unmet clinical need to find drugs or devices or strategies to help reduce the risk.”

The randomized, double-blinded clinical trial recruited 361 patients from 31 medical centers in the United States and Canada. Recruited subjects were previously scheduled for an angiogram with a high likelihood that they would need angioplasty because of a poor stress test or acute coronary syndrome. The subjects also had either a severe loss of kidney function or mild-to- moderate loss of kidney function and another risk factor such as diabetes, low blood pressure or being more than 75 years old. Patients experiencing a heart attack, life-threatening arrhythmia or total kidney failure were excluded.

Patients were split into four groups and intravenously given a small dose, a large dose or two small doses of CMX-2043 — 2.4 mg/kg, 3.6 mg/kg, or two doses of 2.4 mg/kg with 24 hours in between doses, respectively — or a placebo before their angiograms. Researchers followed up with the subjects over a period of 90 days, the primary endpoint being a reduction in kidney injury. The researchers also examined the incidence of major adverse cardiac and kidney events, reduction in heart damage and heart attacks, and major side effects of CMX-2043.

After four days, all four groups had similar rates of kidney injury — 18.6 percent for placebo, 25.6 percent for a small dose, 25.3 percent for a large dose and 18.9 percent for two small doses. Both serum creatinine and glomerular filtration rate tests, common measures of renal health, showed similar kidney function decreases in all four groups after four days.

During the study period, the rates of major heart and kidney events were also similar among the placebo and all three CMX-2043 groups. CMX-2043 did not cause any major side effects in the doses used in this study, Bhatt said. However, he said the prior finding in a smaller study that suggested the drug reduced stenting-related heart attack complications was not confirmed.

“The thought was that this drug had antioxidant and cell membrane stabilizing effects and that these benefits would translate into less kidney cell damage and heart muscle damage,” Bhatt said. “But as is often the case in this field, drugs that seem to be good based on preclinical work, when used in humans don’t always have an effect.”

Bhatt said he is encouraged, though, by the fact that he and his colleagues were able to perform an efficient trial on a group of patients who are notoriously difficult to recruit. Future research can use this model to study other drugs, devices and strategies to prevent contrast-induced kidney injury, he said.

“We showed that such a trial can be done, and in a rigorous way,” Bhatt said. “The challenge now is to find a drug that actually works.”

One possible limitation to the study is the fixed dosing of CMX-2043. While the specific doses and regimens studied by the researchers did not yield any significant kidney protection, larger or more frequent doses may show such benefits.

The trial was funded by Ischemix LLC, the manufacturer of CMX-2043.

Related Content

DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Overlay Init